| (19) |
 |
|
(11) |
EP 1 359 159 A3 |
| (12) |
EUROPEAN PATENT APPLICATION |
| (88) |
Date of publication A3: |
|
21.07.2004 Bulletin 2004/30 |
| (43) |
Date of publication A2: |
|
05.11.2003 Bulletin 2003/45 |
| (22) |
Date of filing: 07.12.1999 |
|
|
| (84) |
Designated Contracting States: |
|
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
| (30) |
Priority: |
07.12.1998 US 206601
07.12.1998 US 111255 P
|
| (62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
99963437.1 / 1137667 |
| (71) |
Applicant: SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. |
|
75016 Paris (FR) |
|
| (72) |
Inventor: |
|
- Dong, Zheng Xin
Holliston, MA 01746 (US)
|
| (74) |
Representative: Hall, Robert Leonard et al |
|
Harrison Goddard Foote, Fountain Precinct Balm Green
Sheffield S1 2JA
Sheffield S1 2JA (GB) |
|
| |
|
(57) The present invention is directed to peptide analogues of glucagon-like peptide-1,
the pharmaceutically-acceptable salts thereof, to methods of using such analogues
to treat mammals and to pharmaceutical compositions useful therefor comprising said
analogues.